Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2006

01-02-2006 | Original Article

IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes

Authors: S. Ryu, J. H. Lee, S. I. Kim

Published in: Clinical Rheumatology | Issue 1/2006

Login to get access

Abstract

Interleukin-17 (IL-17) is a proinflammatory cytokine that is expressed in the synovium T cells of rheumatoid arthritis (RA). This cytokine is implicated in the inflammation and destruction of the joint. However, the role of IL-17 on the production of vascular endothelial factor (VEGF) important to synovial proliferation has still not been identified. In this study, we investigated the effect on cultured rheumatoid fibroblast-like synoviocytes (FLS) of the IL-17 on the production and expression of VEGF, which play an important role in angiogenesis in rheumatoid synovium. IL-17 increased the production of VEGF dose dependently and the mRNA expression of VEGF. These results suggest that IL-17 might influence angiogenesis in RA by up-regulating the expression of VEGF in rheumatoid FLS.
Literature
1.
2.
3.
4.
Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed
5.
Conn G, Soderman DD, Schaeffer MT, Wile M, Hatcher VB, Thomas KA (1990) Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA 87:1323–1327PubMed
6.
Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B et al (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346CrossRefPubMed
7.
Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL et al (1994) Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149–4156PubMed
8.
Nagashima M, Yoshino S, Ishiwata T, Asano G (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22:1624–1630PubMed
9.
Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD (1997) Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β. J Rheumatol 24:1253–1259PubMed
10.
Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F et al (1999) Hypoxia augments cytokine (transforming growth factor-β [TGF-β] and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 115:176–182CrossRefPubMed
11.
Ikeda E, Achen MG, Breier G, Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761–19766CrossRefPubMed
12.
Ben-Av P, Crofford LJ, Wilder RL, Hla T (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372:83–87CrossRefPubMed
13.
Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741PubMed
14.
Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O et al (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269:6271–6274PubMed
15.
Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265CrossRefPubMed
16.
Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS et al (2000) CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 164:5055–5061PubMed
17.
Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155:5483–5486PubMed
18.
Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C et al (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183:2593–2603CrossRefPubMed
19.
Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR et al (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:811–821CrossRefPubMed
20.
Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α by human macrophages. J Immunol 160:3513–3521PubMed
21.
Kurusawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y et al (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43:2455–2463CrossRefPubMed
22.
Matsumoto K, Kanmatsuse K (2002) Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron 91:243–249CrossRefPubMed
23.
Wong CK, Ho CY, Li EK, Lam CW (2000) Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9:589–593CrossRefPubMed
24.
Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L et al (1999) Human interleukin-17: a T cell derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970CrossRefPubMed
25.
Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H et al (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164:2832–2838PubMed
26.
Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161:409–414PubMed
27.
Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3:168–177CrossRefPubMed
28.
Lubberts E, Joosten LAB, van de Loo FAJ, van den Bersselaar LA, van den Berg WB (2000) Reduction of interleukin-17 induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 43:1300–1306CrossRefPubMed
29.
Martel-Pelletier J, Mineau F, Jovanovic D, Di Battista JA, Pelletier JP (1999) Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis Rheum 42:2399–2409CrossRefPubMed
30.
Lubberts E, van den Bersselaar L, Oppers-Wlagreen B, Schwarzenberger P, Coenen-de Roo CJJ, Kolls JK et al (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol 170:2655–2662PubMed
31.
Lubberts E, Joosten LAB, Oppers-Walgreen B, van den Bersselaar L, Chenen-de Roo CJJ, Kolls JK et al (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167:1004–1013PubMed
32.
Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659CrossRefPubMed
33.
Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed
34.
Kim JM, Ho SH, Hahn W, Jeong JG, Park EJ, Lee HJ et al (2003) Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther 10:1216–1224CrossRefPubMed
35.
Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S et al (2002) Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282:735–738CrossRef
36.
Tartour E, Fowwiez F, Joyeux I, Galinha A, Gey A, Claret E et al (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorgenicity of human cervical tumors in nude mice. Cancer Res 59:3698–3704PubMed
37.
Page F, Vives V, Stautes-Fridman C, Fossiez F, Berger A, Cugnenc PH et al (1999) Control of tumor development by intratumoral cytokines. Immunol Lett 68:135–139CrossRefPubMed
38.
Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T et al (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627CrossRefPubMed
39.
Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokine. J Immunol 161:409–414PubMed
40.
Katz Y, Nadiv O, Beer Y (2001) Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a “fine-tuning cytokine” in inflammation process. Arthritis Rheum 44:2176–2184CrossRefPubMed
Metadata
Title
IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes
Authors
S. Ryu
J. H. Lee
S. I. Kim
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-1081-1

Other articles of this Issue 1/2006

Clinical Rheumatology 1/2006 Go to the issue

Original Article

Comparison of intra-articular tenoxicam and oral tenoxicam for pain and physical functioning in osteoarthritis of the knee

Original Article

Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years

Letter

The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs

Case Report

First report of leprosy presenting as acute polyarthritis in the setting of type I downgrading lepra reaction

Original Article

Volume of a wash and the other conditions for maximum therapeutic effect of arthroscopic lavage in rheumatoid knees

Case Report

Familial Mediterranean fever responds well to infliximab: single case experience
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits